Skip to main content
Premium Trial:

Request an Annual Quote

Epistem, Univ. of Manchester Partner on Wound Healing Models

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer diagnostics and biomarker developer Epistem plans to use novel preclinical models for cutaneous wound healing developed by a University of Manchester scientist under a partnership that is supported by a UK government business development program.

Epistem said the partnership, which has been awarded a Knowledge Transfer Partnership from the Technology Strategy Board and the Medical Research Council, will enable the Manchester-based company to expand its range of wound healing models.

Epistem operates three business divisions, including Contract Research Services, Novel Therapies, and Personalized Medicine. The CRS group provides preclinical efficacy testing for drug development companies in Europe, the US, and Japan on a fee-for-service basis.

THE KTP program has assigned an associate to work within Epistem on the project.

The program provides advice and support to identify researchers with expertise to support businesses' goals, and then supports firms as they seek to improve existing products or develop new ones, develop marketing strategies to enter new markets, and develop systems and frameworks for improving efficiencies in staff and processes.